| Outcome Measures: |
Primary: AUCIco,0-tz:Area under the serum insulin icodec concentration-time curve after a single dose, Measured in hours\*pmol/L, From 0 hours to tz hours after IMP administration (day 1) where tz is the time of the last quantifiable concentration|Dose-normalised AUCSema,0-tz: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose, Measured in (hours\*nmol/L)/mg, From 0 hours to tz hours after IMP administration (day 1) where tz is the time of the last quantifiable concentration | Secondary: AUCIco,0-inf: Area under the serum insulin icodec concentration-time curve after a single dose, Measured in hours\*pmol/L, From 0 hours to infinity after IMP administration (day 1)|Cmax,Ico: Maximum observed serum insulin icodec concentration after a single dose, Measured in pmol/L, From 0 hours until last measurement time after IMP administration (day 1)|tmax,Ico: Time to maximum observed serum insulin icodec concentration after a single dose, Measured in hours, From 0 hours until last measurement time after IMP administration (day 1)|t1/2,Ico: Terminal half-life for insulin icodec after a single dose, Measured in hours, Terminal part of the serum insulin icodec concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after IMP administration (day 1)|Dose-normalised AUCSema,0-inf: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose, Measured in (hours\*nmol/L)/mg, From 0 hours to infinity after IMP administration (day 1)|Dose-normalised Cmax,Sema: Maximum observed plasma semaglutide concentration after a single dose divided by dose, Measured in (nmol/L)/mg, From 0 hours until last measurement time after IMP administration (day 1)|tmax,Sema: Time to maximum observed plasma semaglutide concentration after a single dose, Measured in hours, From 0 hours until last measurement time after IMP administration (day 1)|t1/2,Sema: Terminal half-life for semaglutide after a single dose, Measured in hours, Terminal part of the plasma semaglutide concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after IMP administration (day 1)|Adverse events, Number of events, From IMP administration (day 1) to end of follow-up for each treatment period (day 36)
|
